LataMed AI Surpasses 1,000 Platform Subscribers as Mobile Health Apps Near App Store and Google Play Debut

LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence company, announced that it has surpassed 1,000 early-stage platform subscribers while continuing development of mobile healthcare applications for the Apple App Store and Google Play Store. The milestone signals early interest in the company's telehealth infrastructure and healthcare analytics platforms, which are designed to address fragmented healthcare access in emerging markets, particularly Latin America.

According to the company, the applications currently under development aim to support telehealth, healthcare communication, patient engagement, provider coordination, emergency response, and AI-assisted healthcare initiatives. These efforts are part of LataMed AI's broader digital healthcare infrastructure strategy, which focuses on scalable solutions for underserved regions.

Management stated that certain applications are being prepared for anticipated submission to the Apple App Store and Google Play Store, pending continued development, internal testing, platform review, and regulatory considerations. The company emphasized that the applications remain under active development and have not yet been fully commercialized or broadly deployed.

Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., said: "We are continuing to advance development of our mobile healthcare application ecosystem with the goal of expanding accessibility and healthcare connectivity through both Apple and Android mobile platforms. Surpassing 1,000 early-stage users represents an encouraging milestone as we continue refining and expanding our broader digital healthcare infrastructure initiatives."

The company believes that continued onboarding activity and user engagement may provide valuable operational feedback as development progresses and additional platform functionality is evaluated. LataMed AI noted that its technology initiatives remain focused on markets where access to healthcare coordination, telehealth services, and digital tools is limited.

For more information, visit the company's website at https://latamed.ai or review its filings with the U.S. Securities and Exchange Commission at www.sec.gov.